Identificacion De Fallas De Diseño en Plataformas Groupware Mediante Analisis Heuristico

Luna-García, Huizilopoztli; González, Ricardo Mendoza; Martínez, Laura Cecilia Rodríguez; Dı́az, Mario; Rosas, Francisco Javier Luna; González, Alfredo Mendoza

doi:10.6036/8103

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is particularly relevant in a population that is on average older than that of other primary headache disorders, and with more frequent comorbidities. For these reasons, we suggest guidelines proposing onabotulinumtoxinA as the first drug of choice in the treatment of NH [16].…”

Section: Discussionmentioning

confidence: 99%

“…The proportion of patients that discontinued each treatment due to lack of tolerability was estimated. Treatment was selected as per responsible physician criteria and the local standard of care and national guidelines [16]. OnabotulinumtoxinA (AbbVie Inc., North Chicago, IL, USA) was injected in five points in the painful area, with 5 units per point.…”

Section: Variablesmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Primary Nummular Headache: A Series of 183 Patients from the NUMITOR Study

García-Iglesias

Puledda

Echavarría-Íñiguez

et al. 2022

JCM

View full text Add to dashboard Cite

Nummular headache (NH) is a primary headache characterized by superficial coin-shaped pain. NUMITOR (NCT 05475769) is an observational study evaluating the responder rate of preventive drugs in NH patients. The treatment response was assessed between weeks 8 and 12 compared with the baseline. Patients were included between February 2002 and October 2022. Demographic and clinical variables were assessed; treatment response was estimated by 50%, 30%, and 75% responder rates and treatment discontinuation due to inadequate tolerability. A total of 183 out of 282 patients fulfilled eligibility criteria and completed the study. Patients were aged 49.5 (standard deviation (SD): 16.8) years, and 60.7% were female. NH phenotype was a parietal circular pain of four centimeters’ diameter, moderate intensity, and oppressive quality. At baseline, patients had 25 (interquartile range) pain days per month. Preventive treatment was used by 114 (62.3%) patients. The highest 50% and 75% responder rates corresponded to onabotulinumtoxinA (62.5%, 47.5%), followed by gabapentin (43.7%, 35.2%). Oral preventive drugs were not tolerated by 12.9–25%. The present study provides class IV evidence of the effectiveness of oral preventive drugs and onabotulinumtoxinA in the treatment of primary NH. OnabotulinumtoxinA was the most effective and best-tolerated drug, positioning it as first-line treatment of NH.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Variablesmentioning

confidence: 99%